Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia

Keyphrases

• Pediatric 100%
• Hematopoietic Cell Transplantation 100%
• Alemtuzumab 100%
• Severe Aplastic Anemia 100%
• Reduced Intensity Transplantation 100%
• Unrelated Donor Transplantation 75%
• Immune Reconstitution 50%
• Immune Suppression 50%
• Graft-versus-host Disease (GvHD) 25%
• Multicenter Trial 25%
• Immunosuppression 25%
• Overall Survival 25%
• Immunosuppressive Therapy 25%
• Infection Rate 25%
• 5-year Survival 25%
• High Failure Rate 25%
• First Year 25%
• Median Time 25%
• Graft Rejection 25%
• Treatment-related Mortality 25%
• Blood Cancer 25%
• Event-free Survival 25%
• Laboratory Measures 25%
• Neutrophil Engraftment 25%
• Donor Engraftment 25%
• HLA-matched Donor 25%
• Unrelated Donor 25%
• Reduced-intensity Conditioning 25%
• Fludarabine 25%
• Melphalan 25%
• Good Quality of Life 25%
• Platelet Engraftment 25%

Biochemistry, Genetics and Molecular Biology

• Cell Transplantation 100%
• Alemtuzumab 100%
• Hematopoietic Cell 100%
• Immune Reconstitution 50%
• Overall Survival 50%
• Conditioning 50%
• Infection Rate 25%
• Event Free Survival 25%
• Melphalan 25%
• Fludarabine 25%
• Platelet 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Aplastic Anemia 100%
• Alemtuzumab 100%
• Overall Survival 50%
• Malignant Neoplasm 25%
• Infection Rate 25%
• Melphalan 25%
• Immunosuppressive Agent 25%
• Acute Graft Versus Host Disease 25%
• Event Free Survival 25%
• Graft Rejection 25%
• Fludarabine 25%
• Hexachlorophene 25%